<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201549</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000053</org_study_id>
    <nct_id>NCT03201549</nct_id>
  </id_info>
  <brief_title>The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans</brief_title>
  <acronym>E228</acronym>
  <official_title>The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to examine the effect of fructose ingestion on serum FGF-21&#xD;
      levels in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected&#xD;
    to resume in the future; This is not a suspension of IRB approval&#xD;
  </why_stopped>
  <start_date type="Actual">July 30, 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum FGF21 levels</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy volunteers will ingest fructose and have FGF21 levels measured</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>oral fructose challenge</intervention_name>
    <description>Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.</description>
    <arm_group_label>healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18-60&#xD;
&#xD;
          -  BMI 19-25 kg/m2; 19-23 for Asian subjects&#xD;
&#xD;
          -  Stable weight (variation &lt; 3 kg within 6 months of screening visit)&#xD;
&#xD;
          -  Ability to give informed consent in English&#xD;
&#xD;
          -  Use of medically approved form of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting blood glucose &gt;100&#xD;
&#xD;
          -  Hemoglobin A1C% &gt; 6.5%&#xD;
&#xD;
          -  Fasting triglycerides &gt;150&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes&#xD;
             Association criteria&#xD;
&#xD;
          -  Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or&#xD;
             congestive heart failure)&#xD;
&#xD;
          -  Uncontrolled hypertension (BP &gt; 160/100 mmHg on or off antihypertensive medication)&#xD;
             intravenous drug use&#xD;
&#xD;
          -  Recent weight loss (&gt; 3 kg within 6 months of the screening visit)&#xD;
&#xD;
          -  Gastroparesis&#xD;
&#xD;
          -  Inflammatory or irritable bowel disease&#xD;
&#xD;
          -  Malignancy treated with chemotherapy within the past 3 years&#xD;
&#xD;
          -  Depression or psychosis requiring hospitalization&#xD;
&#xD;
          -  Renal insufficiency (creatinine clearance &lt; 40 ml/min)&#xD;
&#xD;
          -  Transaminases &gt; 2x above the normal range&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Pregnancy within 6 months of the screening visit&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Failure to use medically approved contraceptive methods&#xD;
&#xD;
          -  History of surgery for the treatment of obesity (gastric banding, gastric bypass,&#xD;
             gastric stapling)&#xD;
&#xD;
          -  Change in dose of thyroid hormone or antithyroidal medication within 3 months of&#xD;
             screening visit&#xD;
&#xD;
          -  History of alcohol abuse within the past 5 years&#xD;
&#xD;
          -  Fructose intolerance&#xD;
&#xD;
        Exclusionary medications:&#xD;
&#xD;
          -  Oral steroids&#xD;
&#xD;
          -  Metformin&#xD;
&#xD;
          -  Weight loss medications including nonprescription supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Jody Dushay</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

